SEATTLE--(BUSINESS WIRE)--Dendreon Pharmaceuticals LLC, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced it has signed a long-term lease agreement for its current South Lake Union location. The agreement extends Dendreon’s nearly 20-year presence in the Seattle area and will kick off renovation of the 75,000 square foot location to create maximum space efficiency for the Operations and Medical organizations.
“Dendreon has a long history in Seattle so it was important for us to maintain our presence here,” said Jim Caggiano, chief executive officer at Dendreon. “By securing this location we will continue to access the rich pool of local talent who will help us achieve our mission of bringing PROVENGE® (sipuleucel-T) to more men who can benefit from this life-saving treatment.”
After a series of ups and downs since its founding in 1997, Dendreon has emerged as a rapidly growing enterprise on track to record its third profitable year since orchestrating a remarkable turnaround that began in 2015. Dendreon’s current headquarters and one of its immunotherapy manufacturing facilities (IMF) are located in Seal Beach, Calif.; a second IMF is located in Union City, Ga.
Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 30,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif. For more information, please visit www.dendreon.com.